Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
With
Genentech, Inc.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who completed core study and extension study CIGE24IA05E1 up to and including visit 15, without experiencing any significant drug-related adverse events
Patients who have given written informed consent
You may not be if
Patients who had not received study medication for greater than 84 days since visit 15 of study CIGE24IA05E1
Pregnant females or nursing mothers
Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs
